Big pharmaceutical companies, seeking new pathways in cancer treatment, are increasing investments in antibody drug conjugates (ADCs) developed by biotech firms. BMS recently purchased of an ADC from South Korean biotech Orum Therapeutics for $100m. The development of ADCs involves combining chemotherapies with monoclonal antibodies to specifically target cancer cells, reducing side-effects. ADCs are valued at $9.7bn in 2023 and are expected to double to $19.8bn in five years.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some